000109022 001__ 109022
000109022 005__ 20230519145344.0
000109022 0247_ $$2doi$$a10.1007/s12020-020-02560-6
000109022 0248_ $$2sideral$$a121618
000109022 037__ $$aART-2021-121618
000109022 041__ $$aeng
000109022 100__ $$0(orcid)0000-0002-2865-5813$$ade Arriba Munoz, A.$$uUniversidad de Zaragoza
000109022 245__ $$aImpact of adherence on growth response during the first 2 years of growth hormone treatment
000109022 260__ $$c2021
000109022 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109022 5203_ $$aPurpose
Adherence to growth hormone (GH) treatment impacts clinical outcomes. The aim of this study is to assess the impact of adherence to rhGH treatment (2 years) on auxological outcomes.
Methods
Multicentric, retrospective observational study in rhGH-naive GHD/SGA children treated with Saizen (R) during >= 2 years. Growth response was assessed by evaluating the change in height standard deviation score (Delta H SDS) and the index of responsiveness (IoR). Adherence was monitored using EasyPod (TM) Connect device.
Results
A total of 110 patients (3 Spanish centers) were evaluable (GHD n = 76, SGA n = 34). Adherence was 95.6 and 93.9% (year 1, 2). SGA and GHD children showed an increase of 0.6 cm/year and 1.1 cm/year for each 10% adherence modification. Lower adherence was observed in patients with lower pretreatment height velocity (HV) and in patients whose parents had a lower level of education. A positive correlation between index of responsiveness (IoR) during the first and second years with HV SDS during the second year and between IoR2 and adherence (year 1, 2) was observed. The frequency of patients with HV > 1 SD was higher (p = 0.025) among patients with adherence >90%. The best model to predict the height gain(cm) reaching an adjusted R squared of 0.489 involved percentage of adherence, Tanner stage, pretreatment HV, dose of rhGH, and whether the treatment was initiated before or after puberty.
Conclusions
Adherence during the first 2 years of response was very high >90% and showed a negative association with age, pretreatment HV and treatment duration and a positive correlation with the level of parent education.
000109022 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000109022 590__ $$a3.925$$b2021
000109022 591__ $$aENDOCRINOLOGY & METABOLISM$$b79 / 147 = 0.537$$c2021$$dQ3$$eT2
000109022 594__ $$a6.0$$b2021
000109022 592__ $$a0.873$$b2021
000109022 593__ $$aEndocrinology, Diabetes and Metabolism$$c2021$$dQ2
000109022 593__ $$aEndocrinology$$c2021$$dQ2
000109022 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000109022 700__ $$aCancela Muñiz, V.
000109022 700__ $$aAlcon Saez, J.J.
000109022 700__ $$aBeisti, A.
000109022 700__ $$aLlovet, E.
000109022 700__ $$0(orcid)0000-0003-2832-2266$$aLabarta Aizpun, J.I.$$uUniversidad de Zaragoza
000109022 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000109022 773__ $$g72 (2021), 513–523$$pEndocrine (Basingstoke)$$tENDOCRINE$$x1355-008X
000109022 8564_ $$s697175$$uhttps://zaguan.unizar.es/record/109022/files/texto_completo.pdf$$yPostprint
000109022 8564_ $$s2002149$$uhttps://zaguan.unizar.es/record/109022/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000109022 909CO $$ooai:zaguan.unizar.es:109022$$particulos$$pdriver
000109022 951__ $$a2023-05-18-13:18:34
000109022 980__ $$aARTICLE